According to a phase-2 colon-cancer clinical trial, tumors with mismatch-repair deficiency had better treatment outcomes than tumors without mismatch-repair deficiency after administration of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor [16]. This evidence concerns the gene PDCD1 and colonic neoplasm.